Does intraperitoneal CA-125 reflect disease status?
The relationship of serum CA-125 to intraperitoneal (IP) CA-125 was studied in 45 patients with a variety of gynecologic diseases including ovarian carcinoma. In 43 of 45 patients the IP level exceeded the serum level of CA-125. Paracentesis may dramatically alter both levels, thus mimicking surgica...
Gespeichert in:
| Veröffentlicht in: | Gynecologic oncology 1991, Vol.40 (1), p.66-69 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 69 |
|---|---|
| container_issue | 1 |
| container_start_page | 66 |
| container_title | Gynecologic oncology |
| container_volume | 40 |
| creator | Buller, Richard E. Manetta, Alberto Bloss, Jeffrey D. DiSaia, Philip J. Berman, Michael L. |
| description | The relationship of serum CA-125 to intraperitoneal (IP) CA-125 was studied in 45 patients with a variety of gynecologic diseases including ovarian carcinoma. In 43 of 45 patients the IP level exceeded the serum level of CA-125. Paracentesis may dramatically alter both levels, thus mimicking surgical debulking. All IP levels of CA-125 measured at second-look coeliotomy for the ovarian cancer patients were within the normal range of IP CA-125 measured at surgery for benign disease. Therefore, intraperitoneal CA-125 is less sensitive than serum CA-125 in predicting intraperitoneal disease status. Likewise it cannot be used to predict the subgroup of ovarian cancer patients with negative second-look coeliotomy who are destined to develop a recurrence of disease. |
| doi_str_mv | 10.1016/0090-8258(91)90087-L |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80432049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>009082589190087L</els_id><sourcerecordid>80432049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-87b64a2f2338122deaae412a34446bd7277ec989edfc343cc0de7b8937ebb1cb3</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMo4zj6DxS6UXRRzWuaZKMM4xMKbnQd0uQWIp12TFrBf2_GDurK1V3c7xwOH0LHBF8STIorjBXOJZ3Lc0UuFMZS5OUOmhKs5nkh52oXTX-QfXQQ4xvGmGFCJ2hClFSKiClitx3EzLd9MGsIvu9aME22XOSEzrMAdQO2z5yPYCJksTf9EG8O0V5tmghH2ztDr_d3L8vHvHx-eFouytwyKfpciqrghtaUMUkodWAMcEIN45wXlRNUCLBpB7jaMs6sxQ5EJRUTUFXEVmyGzsbedejeB4i9XvlooWlMC90QtcScUcxVAvkI2tDFmFbrdfArEz41wXrjSm9E6I0IrYj-dqXLFDvZ9g_VCtxvaJST_qfbv4nWNHUwrfXxL8Y5JTJx1yMHScaHh6Cj9dBacD4kfdp1_v8hX6lehCA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80432049</pqid></control><display><type>article</type><title>Does intraperitoneal CA-125 reflect disease status?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Buller, Richard E. ; Manetta, Alberto ; Bloss, Jeffrey D. ; DiSaia, Philip J. ; Berman, Michael L.</creator><creatorcontrib>Buller, Richard E. ; Manetta, Alberto ; Bloss, Jeffrey D. ; DiSaia, Philip J. ; Berman, Michael L.</creatorcontrib><description>The relationship of serum CA-125 to intraperitoneal (IP) CA-125 was studied in 45 patients with a variety of gynecologic diseases including ovarian carcinoma. In 43 of 45 patients the IP level exceeded the serum level of CA-125. Paracentesis may dramatically alter both levels, thus mimicking surgical debulking. All IP levels of CA-125 measured at second-look coeliotomy for the ovarian cancer patients were within the normal range of IP CA-125 measured at surgery for benign disease. Therefore, intraperitoneal CA-125 is less sensitive than serum CA-125 in predicting intraperitoneal disease status. Likewise it cannot be used to predict the subgroup of ovarian cancer patients with negative second-look coeliotomy who are destined to develop a recurrence of disease.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/0090-8258(91)90087-L</identifier><identifier>PMID: 1989917</identifier><identifier>CODEN: GYNOA3</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Antigens, Tumor-Associated, Carbohydrate - analysis ; Antigens, Tumor-Associated, Carbohydrate - blood ; Ascitic Fluid - chemistry ; Biological and medical sciences ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Medical sciences ; Ovarian Neoplasms - blood ; Ovarian Neoplasms - diagnosis ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - surgery ; Peritoneal Diseases - diagnosis ; Peritoneal Diseases - metabolism ; Peritoneal Diseases - pathology ; Radioimmunoassay ; Tumors</subject><ispartof>Gynecologic oncology, 1991, Vol.40 (1), p.66-69</ispartof><rights>1991</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-87b64a2f2338122deaae412a34446bd7277ec989edfc343cc0de7b8937ebb1cb3</citedby><cites>FETCH-LOGICAL-c387t-87b64a2f2338122deaae412a34446bd7277ec989edfc343cc0de7b8937ebb1cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/009082589190087L$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19844218$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1989917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buller, Richard E.</creatorcontrib><creatorcontrib>Manetta, Alberto</creatorcontrib><creatorcontrib>Bloss, Jeffrey D.</creatorcontrib><creatorcontrib>DiSaia, Philip J.</creatorcontrib><creatorcontrib>Berman, Michael L.</creatorcontrib><title>Does intraperitoneal CA-125 reflect disease status?</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>The relationship of serum CA-125 to intraperitoneal (IP) CA-125 was studied in 45 patients with a variety of gynecologic diseases including ovarian carcinoma. In 43 of 45 patients the IP level exceeded the serum level of CA-125. Paracentesis may dramatically alter both levels, thus mimicking surgical debulking. All IP levels of CA-125 measured at second-look coeliotomy for the ovarian cancer patients were within the normal range of IP CA-125 measured at surgery for benign disease. Therefore, intraperitoneal CA-125 is less sensitive than serum CA-125 in predicting intraperitoneal disease status. Likewise it cannot be used to predict the subgroup of ovarian cancer patients with negative second-look coeliotomy who are destined to develop a recurrence of disease.</description><subject>Antigens, Tumor-Associated, Carbohydrate - analysis</subject><subject>Antigens, Tumor-Associated, Carbohydrate - blood</subject><subject>Ascitic Fluid - chemistry</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Ovarian Neoplasms - blood</subject><subject>Ovarian Neoplasms - diagnosis</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Peritoneal Diseases - diagnosis</subject><subject>Peritoneal Diseases - metabolism</subject><subject>Peritoneal Diseases - pathology</subject><subject>Radioimmunoassay</subject><subject>Tumors</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLxDAUhYMo4zj6DxS6UXRRzWuaZKMM4xMKbnQd0uQWIp12TFrBf2_GDurK1V3c7xwOH0LHBF8STIorjBXOJZ3Lc0UuFMZS5OUOmhKs5nkh52oXTX-QfXQQ4xvGmGFCJ2hClFSKiClitx3EzLd9MGsIvu9aME22XOSEzrMAdQO2z5yPYCJksTf9EG8O0V5tmghH2ztDr_d3L8vHvHx-eFouytwyKfpciqrghtaUMUkodWAMcEIN45wXlRNUCLBpB7jaMs6sxQ5EJRUTUFXEVmyGzsbedejeB4i9XvlooWlMC90QtcScUcxVAvkI2tDFmFbrdfArEz41wXrjSm9E6I0IrYj-dqXLFDvZ9g_VCtxvaJST_qfbv4nWNHUwrfXxL8Y5JTJx1yMHScaHh6Cj9dBacD4kfdp1_v8hX6lehCA</recordid><startdate>1991</startdate><enddate>1991</enddate><creator>Buller, Richard E.</creator><creator>Manetta, Alberto</creator><creator>Bloss, Jeffrey D.</creator><creator>DiSaia, Philip J.</creator><creator>Berman, Michael L.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1991</creationdate><title>Does intraperitoneal CA-125 reflect disease status?</title><author>Buller, Richard E. ; Manetta, Alberto ; Bloss, Jeffrey D. ; DiSaia, Philip J. ; Berman, Michael L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-87b64a2f2338122deaae412a34446bd7277ec989edfc343cc0de7b8937ebb1cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Antigens, Tumor-Associated, Carbohydrate - analysis</topic><topic>Antigens, Tumor-Associated, Carbohydrate - blood</topic><topic>Ascitic Fluid - chemistry</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Ovarian Neoplasms - blood</topic><topic>Ovarian Neoplasms - diagnosis</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Peritoneal Diseases - diagnosis</topic><topic>Peritoneal Diseases - metabolism</topic><topic>Peritoneal Diseases - pathology</topic><topic>Radioimmunoassay</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buller, Richard E.</creatorcontrib><creatorcontrib>Manetta, Alberto</creatorcontrib><creatorcontrib>Bloss, Jeffrey D.</creatorcontrib><creatorcontrib>DiSaia, Philip J.</creatorcontrib><creatorcontrib>Berman, Michael L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buller, Richard E.</au><au>Manetta, Alberto</au><au>Bloss, Jeffrey D.</au><au>DiSaia, Philip J.</au><au>Berman, Michael L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does intraperitoneal CA-125 reflect disease status?</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>1991</date><risdate>1991</risdate><volume>40</volume><issue>1</issue><spage>66</spage><epage>69</epage><pages>66-69</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><coden>GYNOA3</coden><abstract>The relationship of serum CA-125 to intraperitoneal (IP) CA-125 was studied in 45 patients with a variety of gynecologic diseases including ovarian carcinoma. In 43 of 45 patients the IP level exceeded the serum level of CA-125. Paracentesis may dramatically alter both levels, thus mimicking surgical debulking. All IP levels of CA-125 measured at second-look coeliotomy for the ovarian cancer patients were within the normal range of IP CA-125 measured at surgery for benign disease. Therefore, intraperitoneal CA-125 is less sensitive than serum CA-125 in predicting intraperitoneal disease status. Likewise it cannot be used to predict the subgroup of ovarian cancer patients with negative second-look coeliotomy who are destined to develop a recurrence of disease.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>1989917</pmid><doi>10.1016/0090-8258(91)90087-L</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-8258 |
| ispartof | Gynecologic oncology, 1991, Vol.40 (1), p.66-69 |
| issn | 0090-8258 1095-6859 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80432049 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antigens, Tumor-Associated, Carbohydrate - analysis Antigens, Tumor-Associated, Carbohydrate - blood Ascitic Fluid - chemistry Biological and medical sciences Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Medical sciences Ovarian Neoplasms - blood Ovarian Neoplasms - diagnosis Ovarian Neoplasms - pathology Ovarian Neoplasms - surgery Peritoneal Diseases - diagnosis Peritoneal Diseases - metabolism Peritoneal Diseases - pathology Radioimmunoassay Tumors |
| title | Does intraperitoneal CA-125 reflect disease status? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T17%3A08%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20intraperitoneal%20CA-125%20reflect%20disease%20status?&rft.jtitle=Gynecologic%20oncology&rft.au=Buller,%20Richard%20E.&rft.date=1991&rft.volume=40&rft.issue=1&rft.spage=66&rft.epage=69&rft.pages=66-69&rft.issn=0090-8258&rft.eissn=1095-6859&rft.coden=GYNOA3&rft_id=info:doi/10.1016/0090-8258(91)90087-L&rft_dat=%3Cproquest_cross%3E80432049%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80432049&rft_id=info:pmid/1989917&rft_els_id=009082589190087L&rfr_iscdi=true |